NCT03572478View on ClinicalTrials.gov

Rucaparib and Nivolumab in Patients With Prostate or Endometrial Cancer

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

August 14, 2018

Primary Completion Date

February 29, 2020

Study Completion Date

October 1, 2020

Conditions
Prostate CancerEndometrial Cancer
Interventions
DRUG

Rucaparib

600 mg taken by mouth twice daily.

DRUG

Nivolumab

480 mg given by intravenous (IV) infusion every 4 weeks.

Trial Locations (1)

60637

University of Chicago Medical Center, Chicago

Sponsors
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

collaborator

Clovis Oncology, Inc.

INDUSTRY

lead

University of Chicago

OTHER